Literature DB >> 22392950

Approach to the hypophosphatemic patient.

Erik A Imel1, Michael J Econs.   

Abstract

Hypophosphatemia is commonly missed due to nonspecific signs and symptoms, but it causes considerable morbidity and in some cases contributes to mortality. Three primary mechanisms of hypophosphatemia exist: increased renal excretion, decreased intestinal absorption, and shifts from the extracellular to intracellular compartments. Renal hypophosphatemia can be further divided into fibroblast growth factor 23-mediated or non-fibroblast growth factor 23-mediated causes. Proper diagnosis requires a thorough medication history, family history, physical examination, and assessment of renal tubular phosphate handling to identify the cause. During the past decade, our understanding of phosphate metabolism has grown greatly through the study of rare disorders of phosphate homeostasis. Treatment of hypophosphatemia depends on the underlying disorder and requires close biochemical monitoring. This article illustrates an approach to the hypophosphatemic patient and discusses normal phosphate metabolism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392950      PMCID: PMC3319220          DOI: 10.1210/jc.2011-1319

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  80 in total

1.  X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults.

Authors:  I R Reid; D C Hardy; W A Murphy; S L Teitelbaum; M A Bergfeld; M P Whyte
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

2.  Effects of therapy in X-linked hypophosphatemic rickets.

Authors:  C F Verge; A Lam; J M Simpson; C T Cowell; N J Howard; M Silink
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

3.  Severe hypophosphatemia in hospitalized patients.

Authors:  M A Camp; M Allon
Journal:  Miner Electrolyte Metab       Date:  1990

4.  Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: influence of treatment regimen and parental height.

Authors:  S Balsan; M Tieder
Journal:  J Pediatr       Date:  1990-03       Impact factor: 4.406

5.  X-linked hypophosphatemic rickets without "rickets".

Authors:  M J Econs; J R Feussner; G P Samsa; E L Effman; J B Vogler; S Martinez; N E Friedman; L D Quarles; M K Drezner
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

6.  X-Linked hypophosphatemic rickets: a disease often unknown to affected patients.

Authors:  M J Econs; G P Samsa; M Monger; M K Drezner; J R Feussner
Journal:  Bone Miner       Date:  1994-01

7.  Seizures related to severe hypophosphataemia induced by mechanical ventilation.

Authors:  J P Laaban; L Marsal; M Waked; T K Vuong; J Rochemaure
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

8.  Calcium and phosphorus metabolism in the premature infant.

Authors:  P D Mayne; I Z Kovar
Journal:  Ann Clin Biochem       Date:  1991-03       Impact factor: 2.057

9.  X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry.

Authors:  I R Reid; W A Murphy; D C Hardy; S L Teitelbaum; M A Bergfeld; M P Whyte
Journal:  Am J Med       Date:  1991-01       Impact factor: 4.965

10.  Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets.

Authors:  S A Rivkees; G el-Hajj-Fuleihan; E M Brown; J D Crawford
Journal:  J Clin Endocrinol Metab       Date:  1992-12       Impact factor: 5.958

View more
  44 in total

1.  Severe, reversible dysphagia and malnutrition in a patient with tumour-induced hypophosphataemia.

Authors:  Tone Ramsli; Jørgen Valeur; Mikkel Pretorius; Per Gerlyng
Journal:  BMJ Case Rep       Date:  2018-06-27

2.  Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children.

Authors:  Luisa F Gonzalez Ballesteros; Nina S Ma; Rebecca J Gordon; Leanne Ward; Philippe Backeljauw; Halley Wasserman; David R Weber; Linda A DiMeglio; Julie Gagne; Robert Stein; Declan Cody; Kimber Simmons; Paul Zimakas; Lisa Swartz Topor; Sungeeta Agrawal; Andrew Calabria; Peter Tebben; Ruth Faircloth; Erik A Imel; Linda Casey; Thomas O Carpenter
Journal:  Bone       Date:  2017-02-04       Impact factor: 4.398

3.  Adefovir-induced Fanconi syndrome: diagnostic pearls and perils of late or missed diagnosis.

Authors:  Samuel Shang Ming Lee; Timothy Peng Lim Quek; Cherng Jye Seow; Melvin Khee Shing Leow
Journal:  CEN Case Rep       Date:  2014-03-14

4.  Tumor-induced osteomalacia: experience from a South American academic center.

Authors:  G González; R Baudrand; M F Sepúlveda; N Vucetich; F J Guarda; P Villanueva; O Contreras; A Villa; F Salech; L Toro; L Michea; P Florenzano
Journal:  Osteoporos Int       Date:  2017-03-25       Impact factor: 4.507

Review 5.  Drug-Induced Hypophosphatemia: Current Insights.

Authors:  Efstathia Megapanou; Matilda Florentin; Haralampos Milionis; Moses Elisaf; George Liamis
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

6.  An 18-month-old boy with growth failure and gross motor skill regression.

Authors:  Breanna Clive; Tara Chobotuk
Journal:  Paediatr Child Health       Date:  2017-09-25       Impact factor: 2.253

Review 7.  Congenital Conditions of Hypophosphatemia Expressed in Adults.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-05-14       Impact factor: 4.333

Review 8.  The changing face of hypophosphatemic disorders in the FGF-23 era.

Authors:  Janet Y Lee; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

Review 9.  FGF23 and Associated Disorders of Phosphate Wasting.

Authors:  Anisha Gohil; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2019-09

Review 10.  Fibroblast Growth Factor 23 and Hypophosphatemia: A Case of Hypophosphatemia along the Rickets-Osteomalacia Spectrum.

Authors:  George T Georges; O Nájera; Kurt Sowers; James R Sowers
Journal:  Cardiorenal Med       Date:  2016-09-30       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.